Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 3, 2011, Pages 785-795

  Iwamoto, Takayuki ^a,b   Bianchini, Giampaolo ^a   Qi, Yuan ^a   Cristofanilli, Massimo ^a   Lucci, Anthony ^a   Woodward, Wendy A ^a   Reuben, James M ^a   Matsuoka, Junji ^b   Gong, Yun ^a   Krishnamurthy, Savitri ^a   Valero, Vicente ^a   Hortobagyi, Gabriel N ^a   Robertson, Fredika ^a   Symmans, W Fraser ^a   Pusztai, Lajos ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

cDNA microarray; Gene set analysis; Inflammatory breast cancer; Receptor subtypes

Indexed keywords

ANTHRACYCLINE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INITIATION FACTOR 4A; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; PACLITAXEL; S6 KINASE; TRASTUZUMAB;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INFLAMMATORY BREAST CANCER; LIPID METABOLISM; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STUDENT T TEST; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BREAST NEOPLASMS; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79151482682     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1280-6     Document Type: Article

References (35)

1. SE Singletary C Allred P Ashley LW Bassett D Berry KI Bland PI Borgen G Clark SB Edge DF Hayes LL Hughes RV Hutter M Morrow DL Page A Recht RL Theriault A Thor DL Weaver HS Wieand FL Greene 2002 Revision of the American joint committee on cancer staging system for breast cancer J Clin Oncol 20 17 3628 3636 10.1200/JCO.2002.02.026 12202663 (Pubitemid 34983222)
2. PH Levine SC Steinhorn LG Ries JL Aron 1985 Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (seer) program J Natl Cancer Inst 74 2 291 297 1:STN:280:DyaL2M7jsFGnuw%3D%3D 3856043
3. M Cristofanilli AU Buzdar GN Hortobagyi 2003 Update on the management of inflammatory breast cancer Oncologist 8 2 141 148 1:CAS:528:DC%2BD3sXjsVOmt7w%3D 10.1634/theoncologist.8-2-141 12697939 (Pubitemid 36428280)
4. I Bieche F Lerebours S Tozlu M Espie M Marty R Lidereau 2004 Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature Clin Cancer Res 10 20 6789 6795 10.1158/1078-0432.CCR-04- 0306 1:CAS:528:DC%2BD2cXpslGltL4%3D 10.1158/1078-0432.CCR-04-0306 15501955 (Pubitemid 39383027)
5. F Bertucci P Finetti J Rougemont E Charafe-Jauffret N Cervera C Tarpin C Nguyen L Xerri R Houlgatte J Jacquemier P Viens D Birnbaum 2005 Gene expression profiling identifies molecular subtypes of inflammatory breast cancer Cancer Res 65 6 2170 2178 10.1158/0008-5472.CAN-04-4115 1:CAS:528:DC%2BD2MXisFGgurc%3D 10.1158/0008-5472.CAN-04-4115 15781628 (Pubitemid 40490124)
6. DM Nguyen K Sam A Tsimelzon X Li H Wong S Mohsin GM Clark SG Hilsenbeck RM Elledge DC Allred P O'Connell JC Chang 2006 Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype Clin Cancer Res 12 17 5047 5054 10.1158/1078-0432.CCR-05-2248 1:CAS:528:DC%2BD28XovF2hu70%3D 10.1158/1078-0432.CCR-05-2248 16951220 (Pubitemid 44453330)
7. S Van Laere I Van der Auwera G Van den Eynden P Van Hummelen P van Dam E Van Marck PB Vermeulen L Dirix 2007 Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using affymetrix-based genome-wide gene-expression analysis Br J Cancer 97 8 1165 1174 10.1038/sj.bjc.6603967 10.1038/sj.bjc.6603967 17848951 (Pubitemid 47586999)
8. KR Hess K Anderson WF Symmans V Valero N Ibrahim JA Mejia D Booser RL Theriault AU Buzdar PJ Dempsey R Rouzier N Sneige JS Ross T Vidaurre HL Gomez GN Hortobagyi L Pusztai 2006 Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer J Clin Oncol 24 26 4236 4244 10.1200/JCO.2006.05.6861 1:CAS:528:DC%2BD28XhtVGju7vJ 10.1200/JCO.2006.05.6861 16896004 (Pubitemid 46630780)
9. Y Gong K Yan F Lin K Anderson C Sotiriou F Andre FA Holmes V Valero D Booser JE Pippen Jr S Vukelja H Gomez J Mejia LJ Barajas KR Hess N Sneige GN Hortobagyi L Pusztai WF Symmans 2007 Determination of oestrogen-receptor status and Erbb2 status of breast carcinoma: a gene-expression profiling study Lancet Oncol 8 3 203 211 10.1016/S1470-2045(07)70042-6 1:CAS:528:DC%2BD2sXisVCqsrY%3D 10.1016/S1470-2045(07)70042-6 17329190
10. JS Parker M Mullins MC Cheang S Leung D Voduc T Vickery S Davies C Fauron X He Z Hu JF Quackenbush IJ Stijleman J Palazzo JS Marron AB Nobel E Mardis TO Nielsen MJ Ellis CM Perou PS Bernard 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 8 1160 1167 10.1200/JCO.2008.18.1370 10.1200/JCO.2008.18.1370 19204204
11. VG Tusher R Tibshirani G Chu 2001 Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci USA 98 9 5116 5121 10.1073/pnas.091062498 1:CAS:528:DC%2BD3MXjt1Ons7w%3D 10.1073/pnas.091062498 11309499 (Pubitemid 32397092)
12. A Subramanian P Tamayo VK Mootha S Mukherjee BL Ebert MA Gillette A Paulovich SL Pomeroy TR Golub ES Lander JP Mesirov 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci USA 102 43 15545 15550 10.1073/pnas.0506580102 1:CAS:528:DC%2BD2MXht1ShtrnO 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)
13. S Van Laere I Van der Auwera GG Van den Eynden SB Fox F Bianchi AL Harris P van Dam EA Van Marck PB Vermeulen LY Dirix 2005 Distinct molecular signature of inflammatory breast cancer by cdna microarray analysis Breast Cancer Res Treat 93 3 237 246 10.1007/s10549-005-5157-z 1:CAS:528:DC%2BD2MXhtFWmtrnI 10.1007/s10549-005-5157-z 16172796 (Pubitemid 41441293)
14. F Bertucci P Finetti J Rougemont E Charafe-Jauffret V Nasser B Loriod J Camerlo R Tagett C Tarpin G Houvenaeghel C Nguyen D Maraninchi J Jacquemier R Houlgatte D Birnbaum P Viens 2004 Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy Cancer Res 64 23 8558 8565 10.1158/0008-5472.CAN-04-2696 1:CAS:528:DC%2BD2cXhtVCjs7zE 10.1158/0008-5472.CAN-04-2696 15574762 (Pubitemid 39552068)
15. TA DiMeo K Anderson P Phadke C Feng CM Perou S Naber C Kuperwasser 2009 A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer Cancer Res 69 13 5364 5373 10.1158/0008-5472.CAN-08-4135 1:CAS:528: DC%2BD1MXnvFWqu7k%3D 10.1158/0008-5472.CAN-08-4135 19549913
16. M Shipitsin LL Campbell P Argani S Weremowicz N Bloushtain-Qimron J Yao T Nikolskaya T Serebryiskaya R Beroukhim M Hu MK Halushka S Sukumar LM Parker KS Anderson LN Harris JE Garber AL Richardson SJ Schnitt Y Nikolsky RS Gelman K Polyak 2007 Molecular definition of breast tumor heterogeneity Cancer Cell 11 3 259 273 10.1016/j.ccr.2007.01.013 1:CAS:528:DC%2BD2sXjsVymtL0%3D 10.1016/j.ccr.2007.01.013 17349583 (Pubitemid 46349843)
17. Z Jiang R Gentleman 2007 Extensions to gene set enrichment Bioinformatics 23 3 306 313 10.1093/bioinformatics/btl599 10.1093/bioinformatics/btl599 17127676 (Pubitemid 46323152)
18. B Efron R Tishirani 2007 On testing the significance of sets of genes Ann Appl Stat 1 1 107 129 10.1214/07-AOAS101
19. D Silvera R Arju F Darvishian PH Levine L Zolfaghari J Goldberg T Hochman SC Formenti RJ Schneider 2009 Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer Nat Cell Biol 11 7 903 908 10.1038/ncb1900 1:CAS:528:DC%2BD1MXnvF2rsro%3D 10.1038/ncb1900 19525934
20. F Forozan R Veldman CA Ammerman NZ Parsa A Kallioniemi OP Kallioniemi SP Ethier 1999 Molecular cytogenetic analysis of 11 new breast cancer cell lines Br J Cancer 81 8 1328 1334 10.1038/sj.bjc.6695007 1:CAS:528:DC%2BD3cXls1Kksg%3D%3D 10.1038/sj.bjc.6695007 10604729
21. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 1659 1672 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L 10.1056/NEJMoa052306 16236737 (Pubitemid 41464705)
22. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F 10.1056/NEJMoa052122 16236738 (Pubitemid 41464706)
23. AE Van Pelt S Mohsin RM Elledge SG Hilsenbeck MC Gutierrez A Lucci Jr M Kalidas T Granchi BG Scott DC Allred JC Chang 2003 Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results Clin Breast Cancer 4 5 348 353 10.3816/CBC.2003.n.040 14715110
24. J Hurley P Doliny I Reis O Silva C Gomez-Fernandez P Velez G Pauletti JE Powell MD Pegram DJ Slamon 2006 Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 12 1831 1838 10.1200/JCO.2005.02.8886 1:CAS:528:DC%2BD28XkvVajt7k%3D 10.1200/JCO.2005.02.8886 16549824 (Pubitemid 46638980)
25. SA Limentani AM Brufsky JK Erban M Jahanzeb D Lewis 2007 Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer J Clin Oncol 25 10 1232 1238 10.1200/JCO.2005.05.3306 1:CAS:528:DC%2BD2sXkvFyms78%3D 10.1200/JCO.2005.05.3306 17296975 (Pubitemid 46640569)
26. H Yamauchi M Cristofanilli S Nakamura GN Hortobagyi NT Ueno 2009 Molecular targets for treatment of inflammatory breast cancer Nat Rev Clin Oncol 6 7 387 394 10.1038/nrclinonc.2009.73 1:CAS:528:DC%2BD1MXnslKksrY%3D 10.1038/nrclinonc.2009.73 19468291
27. B Kaufman M Trudeau A Awada K Blackwell T Bachelot V Salazar M DeSilvio R Westlund T Zaks N Spector S Johnston 2009 Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study Lancet Oncol 10 6 581 588 10.1016/S1470-2045(09)70087-7 1:CAS:528:DC%2BD1MXms12jtbY%3D 10.1016/S1470-2045(09)70087-7 19394894
28. KA Gelderman S Tomlinson GD Ross A Gorter 2004 Complement function in mab-mediated cancer immunotherapy Trends Immunol 25 3 158 164 10.1016/j.it.2004.01.008S 1:CAS:528:DC%2BD2cXhsFWjurY%3D 10.1016/j.it.2004.01. 008 15036044
29. R Nahta D Yu MC Hung GN Hortobagyi FJ Esteva 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 5 269 280 10.1038/ncponc0509 1:CAS:528:DC%2BD28Xltlagtbg%3D 10.1038/ncponc0509 16683005 (Pubitemid 43731112)
30. MB Atkins M Hidalgo WM Stadler TF Logan JP Dutcher GR Hudes Y Park SH Liou B Marshall JP Boni G Dukart ML Sherman 2004 Randomized phase ii study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 5 909 918 10.1200/JCO.2004.08.185 1:CAS:528:DC%2BD2cXpsVKisr0%3D 10.1200/JCO.2004.08.185 14990647 (Pubitemid 41103603)
31. I Beuvink A Boulay S Fumagalli F Zilbermann S Ruetz T O'Reilly F Natt J Hall HA Lane G Thomas 2005 The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation Cell 120 6 747 759 10.1016/j.cell.2004.12.040 1:CAS:528:DC%2BD2MXjtVOqt7Y%3D 10.1016/j.cell.2004.12.040 15797377 (Pubitemid 40568794)
32. MM Mita AC Mita QS Chu EK Rowinsky GJ Fetterly M Goldston A Patnaik L Mathews AD Ricart T Mays H Knowles VM Rivera J Kreisberg CL Bedrosian AW Tolcher 2008 Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies J Clin Oncol 26 3 361 367 10.1200/JCO.2007.12.0345 1:CAS:528:DC%2BD1cXitVGntLk%3D 10.1200/JCO.2007.12.0345 18202410 (Pubitemid 351171685)
33. TL Drell J Joseph K Lang B Niggemann KS Zaenker F Entschladen 2003 Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells Breast Cancer Res Treat 80 1 63 70 10.1023/A:1024491219366 1:CAS:528:DC%2BD3sXkvVCksbw%3D 10.1023/A:1024491219366 12889599 (Pubitemid 36851285)
34. KW Crawford WD Bowen 2002 Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines Cancer Res 62 1 313 322 1:CAS:528:DC%2BD38XntV2gug%3D%3D 11782394
35. E Elstner C Muller K Koshizuka EA Williamson D Park H Asou P Shintaku JW Said D Heber HP Koeffler 1998 Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proc Natl Acad Sci USA 95 15 8806 8811 1:CAS:528:DyaK1cXkvFaltr4%3D 10.1073/pnas.95.15.8806 9671760 (Pubitemid 28350570)